{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:56Z","timestamp":1790806856800,"version":"4.1.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41433-021-01922-2","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T06:02:51Z","timestamp":1641880971000},"page":"1532-1545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity\u2014a current review"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-8586","authenticated-orcid":false,"given":"Shing Chuen","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-1754","authenticated-orcid":false,"given":"Pun Yuet","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Ching","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7181-0834","authenticated-orcid":false,"given":"Nicholas Siu Kay","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"1922_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","volume":"172","author":"A Stahl","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, et al. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. 2018;172:278\u201386.","journal-title":"JAMA Pediatr"},{"key":"1922_CR2","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet (Lond, Engl). 2019;394:1551\u20139.","journal-title":"Lancet (Lond, Engl)"},{"key":"1922_CR3","first-page":"233","volume":"102","author":"WV Good","year":"2004","unstructured":"Good WV, Early Treatment for Retinopathy of Prematurity Cooperative G. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233\u201350.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1922_CR4","doi-asserted-by":"crossref","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol. 2001;119:1110\u20138.","DOI":"10.1001\/archopht.119.8.1110"},{"key":"1922_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep27082","volume":"6","author":"JJT Chan","year":"2016","unstructured":"Chan JJT, Lam CPS, Kwok MKM, Wong RLM, Lee GKY, Lau WWY. et al. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy. Sci Rep. 2016;6:1\u20137.","journal-title":"Sci Rep"},{"key":"1922_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0140-6736(91)90742-8","volume":"337","author":"A Hellstr\u00f6m","year":"1991","unstructured":"Hellstr\u00f6m A, Smith LEH, Dammann O. Retinopathy of prematurity. Lancet. 1991;337:83\u20134.","journal-title":"Lancet"},{"key":"1922_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","volume":"63","author":"SJ Kim","year":"2018","unstructured":"Kim SJ, Port AD, Swan R, Campbell JP, Chan RVP, Chiang MF. Retinopathy of prematurity: a review of risk factors and their clinical significance. Surv Ophthalmol. 2018;63:618\u201337.","journal-title":"Surv Ophthalmol"},{"key":"1922_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3928\/23258160-20170630-06","volume":"48","author":"CA Ludwig","year":"2017","unstructured":"Ludwig CA, Chen TA, Hernandez-Boussard T, Moshfeghi AA, Moshfeghi DM. The Epidemiology of Retinopathy of Prematurity in the United States. Ophthalmic Surg Lasers Imaging Retina. 2017;48:553\u201362.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"1922_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/NPM-915142","volume":"10","author":"J Edy Siswanto","year":"2017","unstructured":"Edy Siswanto J, Sauer PJ. Retinopathy of prematurity in Indonesia: Incidence and risk factors. J Neonatal Perinat Med. 2017;10:85\u201390.","journal-title":"J Neonatal Perinat Med"},{"key":"1922_CR10","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s10792-018-0896-0","volume":"39","author":"PPC Chow","year":"2019","unstructured":"Chow PPC, Yip WWK, Ho M, Lok JYC, Lau HHW, Young AL. Trends in the incidence of retinopathy of prematurity over a 10-year period. Int Ophthalmol. 2019;39:903\u20139.","journal-title":"Int Ophthalmol"},{"key":"1922_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5693\/djo.01.2019.08.002","volume":"25","author":"T Bowe","year":"2019","unstructured":"Bowe T, Nyamai L, Ademola-Popoola D, Amphornphruet A, Anzures R, Cernichiaro-Espinosa LA, et al. The current state of retinopathy of prematurity in India, Kenya, Mexico, Nigeria, Philippines, Romania, Thailand, and Venezuela. Digit J Ophthalmol. 2019;25:49\u201358.","journal-title":"Digit J Ophthalmol"},{"key":"1922_CR12","doi-asserted-by":"publisher","first-page":"F337","DOI":"10.1136\/archdischild-2017-313574","volume":"103","author":"R Gerull","year":"2018","unstructured":"Gerull R, Brauer V, Bassler D, Laubscher B, Pfister RE, Nelle M, et al. Incidence of retinopathy of prematurity (ROP) and ROP treatment in Switzerland 2006-2015: a population-based analysis. Arch Dis Child Fetal Neonatal Ed. 2018;103:F337\u2013f42.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"1922_CR13","first-page":"23","volume":"132","author":"LS Han","year":"2019","unstructured":"Han LS, Bedggood A. Incidence of retinopathy of prematurity in Christchurch Hospital, New Zealand over a 10-year period. N. Z Med J. 2019;132:23\u20139.","journal-title":"N. Z Med J"},{"key":"1922_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000280386","volume":"98","author":"A Hoogerwerf","year":"2010","unstructured":"Hoogerwerf A, Schalij-Delfos NE, van Schooneveld MJ, Termote JU. Incidence of retinopathy of prematurity over the last decade in the Central Netherlands. Neonatology. 2010;98:137\u201342.","journal-title":"Neonatology"},{"key":"1922_CR15","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/bjophthalmol-2014-305561","volume":"99","author":"SL Painter","year":"2015","unstructured":"Painter SL, Wilkinson AR, Desai P, Goldacre MJ, Patel CK. Incidence and treatment of retinopathy of prematurity in England between 1990 and 2011: database study. Br J Ophthalmol. 2015;99:807\u201311.","journal-title":"Br J Ophthalmol"},{"key":"1922_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0161-6420(93)31665-9","volume":"100","author":"DB Schaffer","year":"1993","unstructured":"Schaffer DB, Palmer EA, Plotsky DF, Metz HS, Flynn JT, Tung B, et al. Prognostic factors in the natural course of retinopathy of prematurity. the cryotherapy for retinopathy of prematurity cooperative group. Ophthalmology. 1993;100:230\u20137.","journal-title":"Ophthalmology"},{"key":"1922_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000433565","volume":"234","author":"H Enomoto","year":"2015","unstructured":"Enomoto H, Miki A, Matsumiya W, Honda S. Evaluation of oxygen supplementation status as a risk factor associated with the development of severe retinopathy of prematurity. Ophthalmologica. 2015;234:135\u20138.","journal-title":"Ophthalmologica"},{"key":"1922_CR18","first-page":"307","volume":"39","author":"E Bossi","year":"1984","unstructured":"Bossi E, Koerner F, Flury B, Zulauf M. Retinopathy of prematurity: a risk factor analysis with univariate and multivariate statistics. Helv Paediatr Acta. 1984;39:307\u201317.","journal-title":"Helv Paediatr Acta"},{"key":"1922_CR19","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/pr.2013.52","volume":"73","author":"L Gagliardi","year":"2013","unstructured":"Gagliardi L, Rusconi F, Da Fr\u00e8 M, Mello G, Carnielli V, Di Lallo D, et al. Pregnancy disorders leading to very preterm birth influence neonatal outcomes: results of the population-based ACTION cohort study. Pediatr Res. 2013;73:794\u2013801.","journal-title":"Pediatr Res"},{"key":"1922_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM197602122940702","volume":"294","author":"MF Robert","year":"1976","unstructured":"Robert MF, Neff RK, Hubbell JP, Taeusch HW, Avery ME. Association between maternal diabetes and the respiratory-distress syndrome in the newborn. N Engl J Med. 1976;294:357\u201360.","journal-title":"N Engl J Med"},{"key":"1922_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/IAE.0b013e3181ba246f","volume":"30","author":"WC Wu","year":"2010","unstructured":"Wu WC, Ong FS, Kuo JZ, Lai CC, Wang NC, Chen KJ, et al. Retinopathy of prematurity and maternal age. Retin (Phila, Pa). 2010;30:327\u201331.","journal-title":"Retin (Phila, Pa)"},{"key":"1922_CR22","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1167\/iovs.10-6254","volume":"52","author":"M Pons","year":"2011","unstructured":"Pons M, Marin-Casta\u00f1o ME. Nicotine increases the VEGF\/PEDF ratio in retinal pigment epithelium: a possible mechanism for CNV in passive smokers with AMD. Investigative Ophthalmol Vis Sci. 2011;52:3842\u201353.","journal-title":"Investigative Ophthalmol Vis Sci"},{"key":"1922_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5301\/ejo.5000832","volume":"27","author":"L Barker","year":"2017","unstructured":"Barker L, Bunce C, Husain S, Adams GG. Is artificial reproductive technology a risk factor for retinopathy of prematurity independent of the generation of multiple births? Eur J Ophthalmol. 2017;27:174\u20138.","journal-title":"Eur J Ophthalmol"},{"key":"1922_CR24","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1542\/peds.2004-1309","volume":"115","author":"BA Darlow","year":"2005","unstructured":"Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics. 2005;115:990\u20136.","journal-title":"Pediatrics"},{"key":"1922_CR25","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3109\/14767058.2013.764407","volume":"26","author":"JW Lee","year":"2013","unstructured":"Lee JW, McElrath T, Chen M, Wallace DK, Allred EN, Leviton A, et al. Pregnancy disorders appear to modify the risk for retinopathy of prematurity associated with neonatal hyperoxemia and bacteremia. J Matern Fetal Neonatal Med. 2013;26:811\u20138.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"1922_CR26","doi-asserted-by":"publisher","first-page":"F174","DOI":"10.1136\/adc.2009.160366","volume":"95","author":"AK Aralikatti","year":"2010","unstructured":"Aralikatti AK, Mitra A, Denniston AK, Haque MS, Ewer AK, Butler L. Is ethnicity a risk factor for severe retinopathy of prematurity? Arch Dis Child Fetal Neonatal Ed. 2010;95:F174\u20136.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"1922_CR27","first-page":"1963","volume":"31","author":"XY Ke","year":"2011","unstructured":"Ke XY, Ju RH, Zhang JQ, Chen H, Wei EX, Chen XH. Risk factors for severe retinopathy of prematurity in premature infants: a single-center study. Nan Fang Yi Ke Da Xue Xue Bao. 2011;31:1963\u20137.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"1922_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol. 2014;98:507\u201312.","journal-title":"Br J Ophthalmol"},{"key":"1922_CR29","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1167\/iovs.08-2584","volume":"49","author":"LEH Smith","year":"2008","unstructured":"Smith LEH. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49:5177\u201382.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1922_CR30","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","volume":"10","author":"L Pertl","year":"2015","unstructured":"Pertl L, Steinwender G, Mayer C, Hausberger S, P\u00f6schl E-M, Wackernagel W, et al. A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One. 2015;10:e0129383\u2013e.","journal-title":"PLoS One"},{"key":"1922_CR31","doi-asserted-by":"publisher","first-page":"866","DOI":"10.4103\/ijo.IJO_1608_18","volume":"67","author":"R Tewari","year":"2019","unstructured":"Tewari R, Chandra P, Agarwal R, Azad R. Posterior laser barrage in advancing retinopathy of prematurity: a prospective randomized study. Indian J Ophthalmol. 2019;67:866\u201370.","journal-title":"Indian J Ophthalmol"},{"key":"1922_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3928\/01913913-20131112-02","volume":"51","author":"S-D Nicoara","year":"2014","unstructured":"Nicoara S-D, Cristian C, Irimescu I, Stefanut A-C, Zaharie G. Diode laser photocoagulation for retinopathy of prematurity: outcomes after 7 years of treatment. J Pediatr Ophthalmol Strabismus. 2014;51:39\u201345.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"1922_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N. Engl J Med. 2011;364:603\u201315.","journal-title":"N. Engl J Med"},{"key":"1922_CR34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.5301\/ejo.5000176","volume":"22","author":"HA Mintz-Hittner","year":"2012","unstructured":"Mintz-Hittner HA. Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial. Eur J Ophthalmol. 2012;22:685\u20136.","journal-title":"Eur J Ophthalmol"},{"key":"1922_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-019-1067-4","volume":"19","author":"J Lyu","year":"2019","unstructured":"Lyu J, Zhang Q, Chen C, Xu Y, Ji X, Zhao P. Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40\u2009weeks post menstrual age: a retrospective case series study. BMC Ophthalmol. 2019;19:60.","journal-title":"BMC Ophthalmol"},{"key":"1922_CR36","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/bjophthalmol-2017-311662","volume":"103","author":"Y Bai","year":"2019","unstructured":"Bai Y, Nie H, Wei S, Lu X, Ke X, Ouyang X, et al. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity. Br J Ophthalmol. 2019;103:494\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1922_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","volume":"257","author":"EA Sukgen","year":"2019","unstructured":"Sukgen EA, Ko\u00e7luk Y. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2019;257:49\u201355.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1922_CR38","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132:1327\u201333.","journal-title":"JAMA Ophthalmol"},{"key":"1922_CR39","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","volume":"94","author":"R Karkhaneh","year":"2016","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M, Roohipoor R, Ghassemi F, Imani M, et al. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta ophthalmologica. 2016;94:e417\u201320.","journal-title":"Acta ophthalmologica"},{"key":"1922_CR40","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","volume":"56","author":"L Kong","year":"2015","unstructured":"Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Investigative Ophthalmol Vis Sci. 2015;56:956\u201361.","journal-title":"Investigative Ophthalmol Vis Sci"},{"key":"1922_CR41","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology. 2014;121:2212\u20139.","journal-title":"Ophthalmology"},{"key":"1922_CR42","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","volume":"37","author":"G Zhang","year":"2017","unstructured":"Zhang G, Yang M, Zeng J, Vakros G, Su K, Chen M, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone ii treatment-requiring retinopathy of prematurity. Retin (Phila, Pa). 2017;37:710\u20137.","journal-title":"Retin (Phila, Pa)"},{"key":"1922_CR43","doi-asserted-by":"publisher","first-page":"e496","DOI":"10.1111\/aos.12339","volume":"92","author":"S Moran","year":"2014","unstructured":"Moran S, O\u2019Keefe M, Hartnett C, Lanigan B, Murphy J, Donoghue V. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity. Acta ophthalmologica. 2014;92:e496\u20137.","journal-title":"Acta ophthalmologica"},{"key":"1922_CR44","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S0161-6420(96)30487-9","volume":"103","author":"GE Quinn","year":"1996","unstructured":"Quinn GE, Dobson V, Hardy RJ, Tung B, Phelps DL, Palmer EA. Visual fields measured with double-arc perimetry in eyes with threshold retinopathy of prematurity from the cryotherapy for retinopathy of prematurity trial. The CRYO-Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1996;103:1432\u20137.","journal-title":"Ophthalmology"},{"key":"1922_CR45","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","volume":"125","author":"D Lepore","year":"2018","unstructured":"Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018;125:218\u201326.","journal-title":"Ophthalmology"},{"key":"1922_CR46","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","volume":"22","author":"KA Kennedy","year":"2018","unstructured":"Kennedy KA, Mintz-Hittner HA. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS: Off Publ Am Assoc Pediatr Ophthalmol Strabismus. 2018;22:61\u20135.e1.","journal-title":"J AAPOS: Off Publ Am Assoc Pediatr Ophthalmol Strabismus"},{"key":"1922_CR47","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","volume":"155","author":"BC Harder","year":"2013","unstructured":"Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;155:1119\u201324.e1.","journal-title":"Am J Ophthalmol"},{"key":"1922_CR48","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/bjophthalmol-2019-314610","volume":"104","author":"YC Chen","year":"2020","unstructured":"Chen YC, Chen SN. Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation. Br J Ophthalmol. 2020;104:691\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1922_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3109\/09273972.2016.1159232","volume":"24","author":"M Gunay","year":"2016","unstructured":"Gunay M, Sekeroglu MA, Bardak H, Celik G, Esenulku CM, Hekimoglu E, et al. Evaluation of refractive errors and ocular biometric outcomes after intravitreal bevacizumab for retinopathy of prematurity. Strabismus. 2016;24:84\u20138.","journal-title":"Strabismus"},{"key":"1922_CR50","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122:1008\u201315.","journal-title":"Ophthalmology"},{"key":"1922_CR51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jaapos.2009.12.002","volume":"14","author":"HA Mintz-Hittner","year":"2010","unstructured":"Mintz-Hittner HA. Avastin as monotherapy for retinopathy of prematurity. J AAPOS. 2010;14:2\u20133.","journal-title":"J AAPOS"},{"key":"1922_CR52","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137(4):e20153218.","journal-title":"Pediatrics"},{"key":"1922_CR53","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000439182","volume":"234","author":"H-K Kuo","year":"2015","unstructured":"Kuo H-K, Sun IT, Chung M-Y, Chen Y-H. Refractive error in patients with retinopathy of prematurity after laser photocoagulation or bevacizumab monotherapy. Ophthalmologica. 2015;234:211\u20137.","journal-title":"Ophthalmologica"},{"key":"1922_CR54","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS One. 2016;11:e0148019.","journal-title":"PLoS One"},{"key":"1922_CR55","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3928\/23258160-20190605-01","volume":"50","author":"SH Rodriguez","year":"2019","unstructured":"Rodriguez SH, Peyton C, Lewis K, Andrews B, Greenwald MJ, Schreiber MD. et al. Neurodevelopmental outcomes comparing bevacizumab to laser for Type 1 ROP. Ophthalmic Surg Lasers Imaging Retina. 2019;50:337\u201343.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"1922_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000449530","volume":"236","author":"E Alyamac Sukgen","year":"2016","unstructured":"Alyamac Sukgen E, Comez A, Kocluk Y, Cevher S. The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica. 2016;236:139\u201347.","journal-title":"Ophthalmologica"},{"key":"1922_CR57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3928\/01913913-20191030-01","volume":"57","author":"P Chandra","year":"2020","unstructured":"Chandra P, Kumawat D, Agarwal D, Chawla R. Combined vitrectomy and anti-VEGF treatment for stage 4 retinopathy of prematurity with extensive neovascular proliferation. J Pediatr Ophthalmol Strabismus. 2020;57:61\u20136.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"1922_CR58","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5935\/0004-2749.20150090","volume":"78","author":"MK Erol","year":"2015","unstructured":"Erol MK, Coban DT, Sari ES, Bilgin AB, Dogan B, Ozdemir O, et al. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol. 2015;78:340\u20133.","journal-title":"Arq Bras Oftalmol"},{"key":"1922_CR59","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","volume":"37","author":"WC Wu","year":"2017","unstructured":"Wu WC, Shih CP, Lien R, Wang NK, Chen YP, Chao AN, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina. 2017;37:694\u2013701.","journal-title":"Retina"},{"key":"1922_CR60","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","volume":"256","author":"CY Huang","year":"2018","unstructured":"Huang CY, Lien R, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2018;256:479\u201387.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1922_CR61","doi-asserted-by":"publisher","first-page":"e1004","DOI":"10.1111\/aos.14460","volume":"98","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Zhu X, Linghu D, Liang J. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity. Acta Ophthalmologica. 2020;98:e1004\u2013e8.","journal-title":"Acta Ophthalmologica"},{"key":"1922_CR62","doi-asserted-by":"publisher","first-page":"e0223972","DOI":"10.1371\/journal.pone.0223972","volume":"14","author":"YS Chang","year":"2019","unstructured":"Chang YS, Chen YT, Lai TT, Chou HC, Chen CY, Hsieh WS, et al. Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment. PLoS One. 2019;14:e0223972.","journal-title":"PLoS One"},{"key":"1922_CR63","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","volume":"126","author":"YY Fan","year":"2019","unstructured":"Fan YY, Huang YS, Huang CY, Hsu JF, Shih CP, Hwang YS, et al. Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study. Ophthalmology. 2019;126:1567\u201377.","journal-title":"Ophthalmology"},{"key":"1922_CR64","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1001\/jamaophthalmol.2019.4488","volume":"138","author":"ER Crouch","year":"2020","unstructured":"Crouch ER, Kraker RT, Wallace DK, Holmes JM, Repka MX, Collinge JE, et al. Secondary 12-month ocular outcomes of a phase 1 dosing study of bevacizumab for retinopathy of prematurity. JAMA Ophthalmol. 2020;138:14\u201320.","journal-title":"JAMA Ophthalmol"},{"key":"1922_CR65","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","volume":"135","author":"DK Wallace","year":"2017","unstructured":"Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, et al. Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135:654\u20136.","journal-title":"JAMA Ophthalmol"},{"key":"1922_CR66","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","volume":"125","author":"DK Wallace","year":"2018","unstructured":"Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, et al. A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments. Ophthalmology. 2018;125:1961\u20136.","journal-title":"Ophthalmology"},{"key":"1922_CR67","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","volume":"138","author":"DK Wallace","year":"2020","unstructured":"Wallace DK, Kraker RT, Freedman SF, Crouch ER, Bhatt AR, Hartnett ME, et al. Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity. JAMA Ophthalmol. 2020;138:698\u2013701.","journal-title":"JAMA Ophthalmol"},{"key":"1922_CR68","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1067\/mpa.2002.121452","volume":"6","author":"N Fallaha","year":"2002","unstructured":"Fallaha N, Lynn MJ, Aaberg TM Jr, Lambert SR. Clinical outcome of confluent laser photoablation for retinopathy of prematurity. J AAPOS: Off Publ Am Assoc Pediatr Ophthalmol Strabismus. 2002;6:81\u20135.","journal-title":"J AAPOS: Off Publ Am Assoc Pediatr Ophthalmol Strabismus"},{"key":"1922_CR69","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00417-014-2762-8","volume":"253","author":"M Gunay","year":"2015","unstructured":"Gunay M, Sekeroglu MA, Celik G, Gunay BO, Unlu C, Ovali F. Anterior segment ischemia following diode laser photocoagulation for aggressive posterior retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2015;253:845\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1922_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69684-7","volume":"10","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Zhu X, Linghu D, Xu Y, Liang J. Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity. Sci Rep. 2020;10:12695.","journal-title":"Sci Rep"},{"key":"1922_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28987-6","volume":"8","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, Meng Q, Linghu D, Zhao M, Liang J. A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity. Sci Rep. 2018;8:10732.","journal-title":"Sci Rep"},{"key":"1922_CR72","doi-asserted-by":"publisher","first-page":"884","DOI":"10.4103\/ijo.IJO_708_18","volume":"67","author":"V Vedantham","year":"2019","unstructured":"Vedantham V. Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity. Indian J Ophthalmol. 2019;67:884\u20138.","journal-title":"Indian J Ophthalmol"},{"key":"1922_CR73","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1755-3768.2011.02351.x","volume":"91","author":"U Spandau","year":"2013","unstructured":"Spandau U, Tomic Z, Ewald U, Larsson E, Akerblom H, Holmstr\u00f6m G. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol. 2013;91:170\u20135.","journal-title":"Acta Ophthalmol"},{"key":"1922_CR74","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1097\/IAE.0b013e3181cb6151","volume":"30","author":"KA Drenser","year":"2010","unstructured":"Drenser KA, Trese MT, Capone A Jr. Aggressive posterior retinopathy of prematurity. Retina. 2010;30:S37\u2013S40.","journal-title":"Retina"},{"key":"1922_CR75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4419-8871-3_1","volume":"117","author":"S Patan","year":"2004","unstructured":"Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res. 2004;117:3\u201332.","journal-title":"Cancer Treat Res"},{"key":"1922_CR76","first-page":"1217","volume":"41","author":"S Hughes","year":"2000","unstructured":"Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci. 2000;41:1217\u201328.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1922_CR77","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","volume":"142","author":"JT Flynn","year":"2006","unstructured":"Flynn JT, Chan-Ling T. Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol. 2006;142:46\u201359.","journal-title":"Am J Ophthalmol"},{"key":"1922_CR78","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1136\/bjo.84.12.1383","volume":"84","author":"R Axer-Siegel","year":"2000","unstructured":"Axer-Siegel R, Snir M, Cotlear D, Maayan A, Frilling R, Rosenbaltt I, et al. Diode laser treatment of posterior retinopathy of prematurity. Br J Ophthalmol. 2000;84:1383\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1922_CR79","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3928\/0191-3913-20030701-06","volume":"40","author":"Z R\u00e9cs\u00e1n","year":"2003","unstructured":"R\u00e9cs\u00e1n Z, V\u00e1mos R, Salacz G. Laser treatment of zone I prethreshold and stage 3 threshold retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 2003;40:204\u20137.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"1922_CR80","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130:1000\u20136.","journal-title":"Arch Ophthalmol"},{"key":"1922_CR81","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/archophthalmol.2011.1802","volume":"130","author":"RD Patel","year":"2012","unstructured":"Patel RD, Blair MP, Shapiro MJ, Lichtenstein SJ. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol. 2012;130:801\u20132.","journal-title":"Arch Ophthalmol"},{"key":"1922_CR82","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","volume":"248","author":"JY Lee","year":"2010","unstructured":"Lee JY, Chae JB, Yang SJ, Yoon YH, Kim J-G. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol. 2010;248:1257\u201362.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1922_CR83","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/bjo.79.3.267","volume":"79","author":"I Kremer","year":"1995","unstructured":"Kremer I, Nissenkorn I, Lusky M, Yassur Y. Late visual field changes following cryotherapy for retinopathy of prematurity stage 3. Br J Ophthalmol. 1995;79:267\u20139.","journal-title":"Br J Ophthalmol"},{"key":"1922_CR84","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.preteyeres.2009.06.003","volume":"28","author":"AB Fulton","year":"2009","unstructured":"Fulton AB, Hansen RM, Moskowitz A, Akula JD. The neurovascular retina in retinopathy of prematurity. Prog Retin Eye Res. 2009;28:452\u201382.","journal-title":"Prog Retin Eye Res"},{"key":"1922_CR85","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1097\/IAE.0b013e318159ec39","volume":"28","author":"JR Gaitan","year":"2008","unstructured":"Gaitan JR, Berrocal AM, Murray TG, Hess D, Johnson RA, Mavrofrides EC. Anterior segment ischemia following laser therapy for threshold retinopathy of prematurity. Retina. 2008;28:S55\u20137.","journal-title":"Retina"},{"key":"1922_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12264-z","volume":"7","author":"A Gotz-Wieckowska","year":"2017","unstructured":"Gotz-Wieckowska A, Chmielarz-Czarnocinska A, Pawlak M, Gadzinowski J, Mazela J. Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment. Sci Rep. 2017;7:11894.","journal-title":"Sci Rep"},{"key":"1922_CR87","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/IAE.0b013e318296e26d","volume":"34","author":"J Kim","year":"2014","unstructured":"Kim J, Kim SJ, Chang YS, Park WS. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina. 2014;34:77\u201382.","journal-title":"Retina"},{"key":"1922_CR88","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","volume":"155","author":"W-C Wu","year":"2013","unstructured":"Wu W-C, Kuo H-K, Yeh P-T, Yang C-M, Lai C-C, Chen S-N. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Am J Ophthalmol. 2013;155:150\u20138.e1.","journal-title":"Am J Ophthalmol"},{"key":"1922_CR89","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179\u201382.","journal-title":"Ophthalmology."},{"key":"1922_CR90","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/bjophthalmol-2012-302391","volume":"97","author":"I Krebs","year":"2013","unstructured":"Krebs I, Schmetterer L, Boltz A, Told R, V\u00e9csei-Marlovits V, Egger S, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97:266\u201371.","journal-title":"Br J Ophthalmol"},{"key":"1922_CR91","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1523\/JNEUROSCI.15-07-04738.1995","volume":"15","author":"J Stone","year":"1995","unstructured":"Stone J, Itin A, Alon T, Pe\u2019er J, Gnessin H, Chan-Ling T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15:4738\u201347.","journal-title":"J Neurosci"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01922-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01922-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01922-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T23:04:01Z","timestamp":1667689441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01922-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1922"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01922-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"8 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}